Showing 121-130 of 4939 results for "".
Laser Tattoo Removal and the Use of Stacked Treatments
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-tattoo-removal-and-the-use-of-stacked-treatments/19309/Tattoo removal procedures have been offered since the late 1990's, but are more effective than ever. This improvement is due to the implementation of stack treatments, during which four sessions can be performed at one time. To show the advances in this procedure, Dr. Joel Schlessinger walks you thrDr. Kauvar Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-kauvar-discusses-experience-with-gemini-laser/19469/“Treating with the Gemini is very well accepted by patients because both components of the Gemini, the 1064 and the 532nm, are non-invasive lasers. So there's really no real downtime and no recuperation, and the results are predictable in our hands, and patients are very satisfied with their treatLasers in Practice: Devices for Non-Invasive Fat Reduction
https://practicaldermatology.com/topics/general-topics/lasers-in-practice-devices-for-non-invasive-fat-reduction/21998/While most devices are investigational, and long-term studies are needed, early evidence is promising for non-invasive fat reduction.Part 1, 1726 nm lasers: Five dermatologists discuss the laser’s benefits and drawbacks for treating acne and other skin conditions
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24339/Chapter 1 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how they have brought in the new 1726 nm wavelength lasers into their practices, what skin conditions it is most benRosacea: A Closer Look at the Latest Treatment Options
https://practicaldermatology.com/topics/acne-rosacea/rosacea-a-closer-look-at-the-latest-treatment-options/23983/The latest treatments and expanded, responsible choices for treating patients with rosacea.Journal Club: Treating Itch and Lessons from the IL-4 and IL-13 Blockade
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-treating-itch-and-lessons-from-the-il-4-and-il-13-blockade/27025/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Matthew Zirwas, MD, about how evaluations of itch can lead to treatment for atopic dermatitis, and his Journal of Drugs in Dermatology article "Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade."Tazarotene Lotion for Acne
https://practicaldermatology.com/topics/acne-rosacea/tazarotene-lotion-for-acne/23388/Tazarotene Lotion 0.045% offers dermatologists a new option that is effective and well tolerated for treating acne.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.DermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for Tre